Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

doi:10.4254/wjh.v6.i7.520

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6409)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

375

WORD

379

HTML

2630

Figures (1-2)

243

Tables (1-5)

231

Sum=3858

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1197

Download

1354

Sum=2551

Jul 27, 2014 (publication date) through Jan 10, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Hepatol. Jul 27, 2014; 6(7): 520-526
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520

Table 3 Percentage of patients who responded in terms of rapid virologic response, early virologic response, end of treatment virologic response, and sustained virologic response in genotypes 1, 3 and 4 by per protocol analysis

Parameter	Genotype 1	Genotype 3¹	Genotype 4
	(n/N)	(n/N)	(n/N)
RVR	25.9% (7/27)	74.1% (40/54)	58.8% (10/17)
EVR	74.1% (20/27)	100% (49/49)	88.2% (15/17)
ETVR	84.2% (16/19)	89.8% (44/49)	75.0% (12/16)
SVR	60.0% (12/20)	76.6% (36/47)	60.0% (9/15)

¹Includes one patient with genotype 2; n: Number of responding patients; N: Total number of patients studied; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response; ETVR: End of treatment virologic response.

Citation: Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
URL: https://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i7.520